FindTrial
Sign In

Impact of sugars on patients diagnosed with COVID

Impact of glycemic variability on the outcome of patients diagnosed with SARS-COV 2 virus

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/12/029712
Enrollment
1000
Registered
2020-12-10
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Not applicable: Not applicable Control Intervention1: NIL: NIL

Sponsors

Shravanthi Naidu S Woodayagiri
Lead Sponsor
Swathy Moorthy
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Patients >18 years who have been diagnosed with SARS COV-2 infection by RTPCR analysis of the nasal swab specimen taken Type2 diabetes and are on treatment Patients with impaired glucose tolerance FBS >100mg/dl but PPBS >140mg/dl but Stress induced hyperglycemia Patients with no history of impaired glucose tolerance but have â?? Newly diagnosed diabetic patients (as per WHO guidelines)

Exclusion criteria

Exclusion criteria: Patients GDM Patients with chronic illness such as Malignancies Autoimmune disease Chronic disease requiring steroids Smokers

Design outcomes

Primary

MeasureTime frame
Clinical recovery of the patientTimepoint: At baseline at 4 weeks—

Secondary

MeasureTime frame
complications during the hospital stay and immediately after dischargeTimepoint: At baseline and 4 weeks—

Countries

India

Contacts

Public ContactShravanthi Naidu S Woodayagiri

Sri Ramachandra Institute of Higher Education and Research

swathy.murali@gmail.com9444016401

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026